Business
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS)
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific Advisory BoardRADNOR, Pa., Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced it has made key advances in developing NRX-101 to treat Chronic Pain.\n\n \n \n \n \n \n \n\n \nThe Company has signed a License Agreement for US Patent 8,653,120 that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. Additional published non-clinical data previously reported demonstrate that NRX-101 is not neurotoxic1 and not addictive.2\nNRx has signed an agreement with Dr. Vania Apkarian, Professor of Physiology, Anesthesia, Surgery, and Neuroscience Institute, Northwestern University Feinberg School of Medicine to join the NRx Pharmaceuticals Scientific Advisory Board (SAB). Over his career, Dr. Apkarian has been devoted to unravelling brain mechanisms that underlie acute and chronic pain, and more generally how the brain dynamically processes information that gives rise to perception. This has included important research into the use of D-cycloserine in Chronic Pain.\n\"We delighted welcome Dr. Apkarian to the NRx SAB,\" said Jonathan Javitt, Chief Scientist and Founder of NRx Pharmaceuticals. \"Adding a scientist of Vania's caliber will be invaluable to advancing our clinical program in Chronic Pain.\"\nNRX-101 Indication – Chronic Pain\nIn June 2023, the Company announced a focus on chronic pain as the next focus on NRX-101's development.DCS has been shown to modulate the Pain Pathway at each point in the chain: pain transmissionat dorsal horn of the spinal cord, pain perception in the thalamus (\"paleo brain\"), and pain memory and processing between the paleo brain and the cortex.In experimental mouse models and clinical studies, NMDA antagonists ha...